Kornimate/medical-research-clean huggingface dataset:
use of circadian reset technology to alter rem sleep and appetitive control in patients with binge eating disorder

Conditions: Binge-Eating Disorder

Summary: this project includes testing circadian reset technology (crt) on frequency of binge eating in a sample of 40 individuals with binge eating disorder. participants will be randomized to one of two groups. both groups use a virtual reality (vr) headset for 10 minutes (5 upon waking, 5 before sleep) daily for 1 month. one group will use the crt software on the headset and the other group will use a software intended to be a control. measures will be taken at baseline and 1-month. the researchers anticipate that use of crt will improve sleep quality leading to increased appetitive control.

this is a clinical trial with total of 40 individuals with binge eating disorder ages 18 or older will be enrolled to use a vr headset with crt or without. examine whether 1-month of crt alters binge eating frequency. secondary outcomes include examining whether 1-month of crt alters sleep quality, appetite regulation, functional magnetic resonance imaging (fmri) measures of functional connectivity, food-based impulsivity/craving, and mood. assessments are completed at baseline, weekly for 1 month, and then a final 1-month follow-up. procedures include a screening/baseline phase to determine eligibility, gather baseline measures, and set-up on vr headset. weeks 1 through 4 include using a vr headset twice a day for 5 minutes each. an online weekly survey will be completed, as well as daily ecological momentary assessment (ema) surveys related to eating patterns throughout each day. the final visit will include a repeat of the baseline procedures including the fmri. all recruitment and study procedures will take place through the center of excellence in eating and weight disorders at the icahn school of medicine at mount sinai.

Eligibility criteria:
inclusion criteria: * ages 18+ * diagnosed with binge eating disorder using eda-5 * english-speaking exclusion criteria: * pregnancy * acute suicide risk/active suicidal ideation * psqi score \<5 indicating good sleep quality * a condition that may create a risk while using the vr headset including risk of falls, seizures, a heart condition, migraines, an eye or vision condition, or an inner ear condition.

Keywords: binge eating disorder eating disorder eating disorder treatment circadian rhythm technology virtual reality
opc-1085el in the treatment of primary open angle glaucoma or ocular hypertension in chinese subjects

Conditions: Open Angle Glaucoma or Ocular Hypertension

Summary: it is a phase iii, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of opc-1085el in the treatment of primary open angle glaucoma or ocular hypertension in chinese subjects. it is planned that 240 subjects (120 in each group) will be randomly assigned to receive opc-1085el or 0.005% latanoprost ophthalmic solution (latanoprost) at a ratio of 1:1.

the trial includes 2 period: 1. screening period: 4 weeks. for subjects entering the screening period, 0.005% latanoprost will be administered for 4 consecutive weeks, one drop for each eye, once per day. 2. evaluation period: 8 weeks. subjects who are eligible are randomly assigned to the opc-1085el group or 0.005% latanoprost group at a ratio of 1:1, one drop for each eye, once per day.

Eligibility criteria:
inclusion criteria: 1. gender: unlimited 2. hospitalization status: outpatients 3. age: 20-80 years old 4. subjects with both eyes diagnosed as primary open angle glaucoma or ocular hypertension. \[at the end of the screening period\] 5. iop: after 4 weeks treatment with 0.005% latanoprost, the unilateral eye with a pre-dose iop from 18 mmhg to \<30 mmhg, and iop \<30 mmhg in the contralateral eye. exclusion criteria: 1. subjects with a best-corrected visual acuity ≤ 0.2. 2. subject with any secondary glaucoma such as exfoliative or pigmented glaucoma. 3. subjects who cannot stop using contact lenses during the trial. 4. subjects who are judged by investigators to be at risk when receiving carteolol hydrochloride or 0.005% latanoprost as monotherapy. 5. subjects who are allergic to any ingredients in carteolol or latanoprost.
prevention of recurrence of crohn's disease by fecal microbiota therapy (fmt)

Conditions: Crohn's Disease

Summary: the objective of this trial is to assess if fecal microbiota therapy (fmt) can reduce the risk of endoscopic recurrence of crohn's disease (cd) in patients after intestinal resection. the specific outcomes of fmt to be examined are: 1) endoscopic appearance, 2) clinical symptoms, 3) safety and tolerability, and 4) microbial diversity. the research team hypothesizes that fmt will prevent establishment of "pro-inflammatory" microbiome after surgery, leading to a reduced probability of recurrence of macroscopic inflammation. it is also hypothesized that fmt will be safe and well-tolerated in these patients.


Eligibility criteria:
inclusion criteria (patients): * adults (age \> 18) * confirmed diagnosis of crohn's disease (cd), based on endoscopy, histology and imaging (confirmed by study pi for each site) * ileo-cecal resection or terminal ileal resection for cd within 30 days prior to enrollment * resection margins \& anastomosis free of active inflammation based on histology and surgical description (confirmed by study pi for each site) * no therapy to prevent post-operative recurrence of cd. a 30-day wash-out period for anti- tumor necrosis factors (tnf)s, thiopurines, antibiotics will be required prior to enrollment. exclusion criteria (patients): * diagnosis of indeterminate colitis * women who are pregnant or nursing * patients who are unable to give informed consent * patients who are unable or unwilling to undergo colonoscopy with moderate sedation (\>asa class ii) * patients who have previously undergone fmt * patients who have a confirmed malignancy or cancer * participation in a clinical trial in the preceding 30 days or simultaneously during this trial * probiotic use within 30 days of start date * decompensated cirrhosis * congenital or acquired immunodeficiencies * chronic kidney disease as defined by a gfr \<60ml/min/1.73m2 44 * history of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia from colonoscopy

Keywords: prevention recurrence fecal microbiota therapy
prospective trial on immunochemotherapy plus autologous stem cell transplantation (sct) and allogenic sct in primary mantle-cell-lymphoma

Conditions: Mantle-Cell Lymphoma

Summary: the purpose of this study is to improve the overall survival of mantle-cell-lymphoma (mcl) by a new concept of treatment with primary curative intention consisting of six courses of immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (sct) and hla-identical allogenic sct after a dose-reduced conditioning regimen of total body irradiation (tbi) with 2 gy and fludarabine in younger patients with primary mantle-cell-lymphoma

with a median overall survival of approximately 3 years, mcl has the poorest prognosis of all nhl entities. no potentially curative therapy has been established yet as even more intensive therapies including high-dose chemotherapy plus autologous sct show only moderate improvement of the prognosis of mcl. allogenic sct seems to have an immunological mechanism of action in nhl, which is commonly known as graft-versus-lymphoma effect. this trial´s purpose is to improve the overall survival in patients younger than 55 years with primary mcl by sequentially combining autologous sct and allogenic sct after the application of 6 courses of immunochemotherapy and high-dose chemotherapy.

Eligibility criteria:
inclusion criteria: 1. first diagnosis of mantle-cell-lymphoma without any previous therapies except for pre-phase treatment consisting of steroids 2. age 18 to 55 years 3. confirmed cd20-expression on lymphocytes 4. effective methods of contraception and negative pregnancy test 5. sufficient compliance 6. written patient´s informed consent exclusion criteria: 1. manifest cardiac insufficiency, not compensated 2. congestive cardiomyopathy 3. chronic pulmonary disease including hypoxemia 4. severe hypertension, not condensable with drugs 5. severe diabetes mellitus not condensable with drugs 6. renal insufficiency ( serum creatinin \> 2,0 mg/dl, other than lymphoma related) 7. liver impairment ( transaminases value more than 3 x upper normal value or bilirubin \> 2,0 mg/dl, other than lymphoma related) 8. hiv-infection 9. active hepatitis b-infection if continuous virostatic treatment is not possible 10. active hepatitis c-infection 11. clinical signs of cerebrovascular insufficiency or cerebral damages 12. pregnancy, lactation or inadequate contraception in women of childbearing age 13. severe psychiatric disorders 14. transplantation in the past

Keywords: mantle-cell-lymphoma mcl non hodgkin´s lymphoma nhl immunochemotherapy r-chop chop high-dose chemotherapy beam hd-beam autologous stem cell transplantation reduced conditioning regimen unrelated donor sibling donor total body irradiation tbi allogenic stem cell transplantation absct asct fludarabine+tbi
efficacy of tegoprazan based bismuth quadruple therapy for helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: this study aims to investigate eradication rate, drug compliance, and adverse events in patients with confirmed helicobacter pylori infection between tegoprazan, bismuth, metronidazole, and tetracycline for 14 days (tbmt) and ppi, bismuth, metronidazole, and tetracycline for 14 days (lbmt)

this is a multi-center, double-blind, randomized, active-controlled study.

Eligibility criteria:
inclusion criteria: patients who male or female aged 19 to 75 years old and fall under the following conditions with confirmed helicobacter pylori infection exclusion criteria: 1. patients who have h.pylori eradication history 2. patients with history of gastric cancer surgery 3. patients who have taken antibiotics within 4 weeks prior to trial 4. a person who taking hiv protease inhibitors (atazanavir, nelfinavir) or a drug containing rilpivirine 5. pregnant or breastfeeding women
treg activation in the treatment of the pelade (alopecia areata)

Conditions: Alopecia Areata

Summary: in a prospective pilot study the investigators showed that low doses of il2 could be beneficial for severe aa inducing a long lasting regrowth in 4 out of the 5 patients treated. the objective of this study is to compare the long term efficacy of low doses of il2 versus placebo in a multicenter prospective randomized double blind study.


Eligibility criteria:
inclusion criteria: * of more than 18 years old, * affiliated to the social security system, * clinical diagnosis of alopecia areata, * 50 % of the surface of the scalp affected * last flaire started less than one year * alopecia areata resisting to at least 1 systematic treatment including phototherapy (uvb or puva), general corticosteroid therapy or methotrexate * signature of the informed consent exclusion criteria: * pregnancy or refusal of contraception at the women old enough to procreate, * refusal of contraception at the men * local treatment (dermocorticoïdes, minoxidil) or systematism (oral corticosteroid therapy, méthotrexate or the other immunosuppresseur) since less than 2 less, * evolutionary autoimmune cancer or disease or in forgiveness * excessive grip(taking) of alcohol (upper to 3 glasses of wine a day or one pre-lunch drink a day) * seropositivity vhc, vhb, or hiv * patient presenting a severe renal and/or hepatic insufficiency, * presenting patient one zoned, the chicken pox, the herpes, the tuberculosis, an evolutionary infectious disease, a respiratory failure ... * vulnerable person (nobody under guardianship minor(miner), adults, deprived of freedom) * ic in the treatment(processing) by il-2r * presenting a contraindication to proleukinr
skeletal muscle energy metabolism in undernourished patients with gastrointestinal cancer

Conditions: Undernutrition; Gastrointestinal Cancer

Summary: undernutrition associated with cancer, or cancer cachexia results from a deterioration of the energy balance that leads to a gradual mobilization of energy reserves in the body and to increasing deterioration of the nutritional status of patients. this will thus significantly reduce quality of life and survival of patients with a lower tolerance to cancer treatments. despite undeniable progress in knowledge, many pathophysiological mechanisms remain few or not explored, which could explain that there is still no satisfactory therapeutic solution to halt the gradual deterioration of the nutritional status of patients. in this sense, apart from preclinical data obtained in animal models, there is currently no clinical study on the functioning of skeletal muscle energy metabolism in undernourished patients suffering of cancer.


Eligibility criteria:
case group selection criteria: inclusion criteria: * 18 years ≤ age ≤ 80 years * colorectal pancreatic cancer * undernutrition related to cancer (weight loss \> 5% weight in one month or 10% in 6 months) * indication to systemic chemotherapy * indication to the development of an implantable port * life expectancy ≥ 3 months * who general status ≤ 2 * patients affiliated to social security scheme * informed consent signed by the patient exclusion criteria: * pregnant or breastfeeding women * unbalanced diabetes * systemic corticosteroid treatment * any severe uncontrolled medical condition * alopecia control group selection criteria: inclusion criteria: * 18 years ≤ age ≤ 80 years * colorectal pancreatic cancer * indication adjuvant chemotherapy * indication to the development of an implantable port * life expectancy ≥ 3 months * who general status ≤ 2 * patients affiliated to social security scheme * informed consent signed by the patient exclusion criteria: * pregnant or breastfeeding women * undernutrition related cancer (weight loss \> 5% weight in one month or 10% in 6 months) * unbalanced diabetes * systemic corticosteroid treatment * any severe uncontrolled medical condition * alopecia

Keywords: undernutrition gastrointestinal cancer skeletal muscle energy metabolism
diagnosis of periodontal disease using genetic marker in saliva

Conditions: Chronic Periodontitis

Summary: the purpose of the present study is to identify the novel periodontal disease biomarkers using differentially expressed microrna in the saliva. the severity of chronic periodontal diseases and the time of pre- and post-treatment are major classification criteria. the obtained data will secure the foundation for the development of a new non-invasive diagnostic methods for early diagnosis \& prognosis prediction of periodontal disease.


Eligibility criteria:
inclusion criteria: a. severe periodontal disease * patients with chronic severe periodontitis * primary treatment of periodontal scaling, subgingival curettage is required, and the general progress of the protocol agreed with the basic periodontal therapy patients. * subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing a. moderate periodontal disease * patients with chronic moderate periodontitis * primary treatment of periodontal scaling, subgingival curettage is required, and the general progress of the protocol agreed with the basic periodontal therapy patients. * subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing c. healthy control * healthy periodontal patients ( more than 20 permanent teeth are present , in all parts of deep periodontal pockets measuring 4mm or less, and height is 2mm or less clinical attachment person) * subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing exclusion criteria: * received periodontal treatment within the last six months * recently taken antibiotics within 3 months if you need a prescription antibiotic prophylaxis * taking the drug can affect periodontal status for a long period of time * pregnant or breastfeeding * in case of oral inflammatory mucosal disease (lichen planus, etc.) * a history of alcoholism or drug abuse if * other special systemic disease (high blood pressure) * ages under 18
eeg in children with unilateral cerebral injury during action and action observation(aoe)

Conditions: Cerebral Palsy; Child

Summary: to study the reactivity of the mu rhythm during action and action-observation by eeg in children with unilateral cerebral injury.


Eligibility criteria:
inclusion criteria: * unilateral cerebral injury * hemiplegia exclusion criteria: * visual or mental or cognitive impairment * no health insurance

Keywords: electroencephalography mu rhythm sensorimotor cortex unilateral cerebral palsy child
swoc activities on balance, gait and endurance in children with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: autism spectrum disorder (asd) is a developmental disorder characterized by challenges in social communication, social interaction, repetitive behaviors, and restrictive interests. affecting 0.2-2% of children, asd often includes motor growth retardation, which worsens over time. the disorder is more commonly diagnosed in boys, and its cause is believed to be genetic, with environmental stimuli potentially activating certain genes. this study aims to explore the effects of standardized walking obstacle course (swoc) activities on balance, gait, and endurance in children with asd, seeking to discover novel treatment techniques that could enhance clinical practices and improve motor skills in these children. this randomized controlled trial will be conducted over 10 months, with data collected from the lahore autism center and psrd hospital in lahore, punjab. the sample will include 44 children with confirmed asd, aged 8 to 12 years, divided into two groups: one undergoing swoc activities and the other receiving conventional physiotherapy. interventions will occur 4 days a week for 30-40 minutes each day. pre- and post-treatment measurements will be taken using the pediatric balance scale (pbs), the 6-minute walk test (6mwt), and functional gait assessment (fga). data will be analyzed using spss version 24, with statistical significance set at p = 0.05.

4 weeks treatment plan. group a: a randomized controlled trial investigate the effect of a standard walking obstacle course activities on balance, gait and endurance in children with asd. activity could include navigating obstacles of varying height and width balancing on beam, stepping over hurdles and walking on different surfaces. 2-3 times for 4 weeks. balance beam stepping stones hurdle markers soft mats balance activities gait and endurance activities group b: either receive no interventions or engages in a different form of physical activities that doesn't focus on balance gait and endurance e.g standard physical education activities like walking, running climbing, jumping along with applied behavioral therapy, speech therapy and customized physical therapy. 2-3 times for 4 weeks.

Eligibility criteria:
inclusion criteria: * children with confirmed diagnosis of asd. * age of patients 8 to 12 year. * both male and female. * fall less than 15 times in 30 seconds in flamingo balance scale test. exclusion criteria: * severe physical impairment. * severe intellectual impairment. * comorbid conditions that could prevent participation.

Keywords: autism spectrum disorder balance standardized obstacle course pediatric balance scale 6-minute walk test
type 2 diabetes post exercise arterial stiffness

Conditions: Type 2 Diabetes

Summary: the overall aim of this research proposal is to determine the impact of glp1 agonists on post-exercise arterial stiffness. therefore, the investigators will examine the cardiovascular responses to exercise in individuals with type 2 diabetes mellitus (t2dm) taking these medications during and following a graded maximal exercise test.

type 2 diabetes mellitus (t2dm) is a significant public health concern associated with increased cardiovascular morbidity and mortality. notably, individuals with t2dm often exhibit increased arterial stiffness, a key indicator of cardiovascular risk. pharmacological interventions such as glp1 agonists have emerged as crucial treatments for t2dm, offering glycemic control and potential cardiovascular benefits, including improvements in blood pressure and arterial stiffness. however, while the effects of glp1 agonists on glycemic control and blood pressure regulation have been explored, their impact on arterial stiffness, specifically in response to exercise, remains largely unexplored in individuals with t2dm. arterial stiffness is a critical marker of cardiovascular health, and its reduction is associated with decreased cardiovascular risk which include lowered blood pressure. therefore, the overall aim of this research is to investigate whether glp1 agonists attenuate arterial stiffness post exercise and reduce peak exercise blood pressure in individuals with t2dm.

Eligibility criteria:
inclusion criteria: individuals diagnosed with type 2 diabetes mellitus (t2dm). * age between 18 and 60 years old. * currently receiving treatment with a glucagon-like peptide 1 (glp1) agonist for the management of t2dm for a minimum duration of six months. * for control group no current use of a glucagon-like peptide 1 (glp1) agonist for the management of type 2 diabetes mellitus (t2dm). * hba1c levels between 6.5-8% * body mass index (bmi) within the range of 25 to 40 kg/m2. exclusion criteria: * coronary heart disease. * pulmonary disease (e.g. asthma, chronic obstructive pulmonary disease) * neurological disorders (e.g. alzheimer's disease, dementia) * congestive heart failure. * peripheral vascular disease. * liver failure. * kidney failure. * alcohol abuse. * drug abuse. * smoking. * hypertension (defined as systolic blood pressure ≥ 140 mmhg or diastolic blood pressure ≥ 90 mmhg) * insulin therapy for the management of t2dm * severe obesity (defined as body mass index \>40 kg/m2); * pregnancy * non-english speaking individuals
a study to assess the safety and efficacy of a daily disposable contact lens

Conditions: Myopia

Summary: the objective of this study is to evaluate the safety and efficacy of the bausch \& lomb daily disposable tint contact lens (test) compared to a currently marketed daily disposable cosmetic tint contact lens (control).


Eligibility criteria:
inclusion criteria: * subjects must have clear central corneas and be free of any anterior segment disorders. * subjects must be adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand. * subjects must be correctable through spherocylindrical refraction to 32 letters (0.3 logmar) or better (distance, high contrast) in each eye. * subjects must be of asian descent. * subjects must require plano or myopic correction and must require contact lens correction from plano to -6.00 d in both eyes. exclusion criteria: * subjects who have any systemic disease affecting ocular health. * subjects using any systemic or topical medications that will, in the investigator's opinion, affect ocular physiology or lens performance. * subjects with an active ocular disease or are using any ocular medication. * subjects with any "present" finding during the slit lamp examination that, in the investigator's judgment, interferes with contact lens wear. * subjects with any scar or neovascularization within the central 4 mm of the cornea. subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the investigator's judgment, does not interfere with contact lens wear, are eligible for this study. * subjects who currently wear monovision, multifocal, or toric contact lenses. * subjects who are adapted wearers of 1-day acuvue define daily disposable cosmetic tint contact lenses.